A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer.

Mingyi JuLongyang JiangQian WeiLifeng YuLianze ChenYan WangBaohui HuPing QianMing ZhangChenyi ZhouZinan LiMinjie WeiLin ZhaoJiali Han

Published in: OncoTargets and therapy (2021)

Our findings demonstrated a TME-related signature which can independently predict both the RFS and OS of LIHC patients, highlighting the predictive potential of the signature for immunotherapy response and sorafenib resistance, potentially enabling more precise and personalized sorafenib treatment in LIHC in the future.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
human health
climate change